Holen Sie sich die Stockscreener-App
23.94
3.86%
-0.96
Handel nachbörslich:
23.97
0.03
+0.13%
Schlusskurs vom Vortag:
$24.90
Offen:
$24.9
24-Stunden-Volumen:
904.63K
Relative Volume:
0.82
Marktkapitalisierung:
$3.21B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.09M
KGV:
-15.35
EPS:
-1.56
Netto-Cashflow:
$-160.51M
1W Leistung:
-2.13%
1M Leistung:
+3.06%
6M Leistung:
+75.90%
1J Leistung:
+52.78%
1-Tages-Spanne:
$23.53
$25.42
1-Wochen-Bereich:
$23.45
$25.42
52-Wochen-Spanne:
$9.60
$25.42
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Firmenname
Centessa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
44 7391 789784
Adresse
3RD FLOOR, ALTRINCHAM, CHESHIRE
Vergleichen Sie CNTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
23.94 | 3.34B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-29 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-05-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-07-18 | Eingeleitet | Oppenheimer | Outperform |
| 2023-11-15 | Hochstufung | Jefferies | Hold → Buy |
| 2023-10-26 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | Eingeleitet | Evercore ISI | Outperform |
| 2023-06-12 | Eingeleitet | Guggenheim | Buy |
| 2023-03-17 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-12 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Centessa Pharmaceuticals Plc Adr Aktie (CNTA) Neueste Nachrichten
Centessa Pharmaceuticals stock hits 52-week high at 25.35 USD By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals stock hits 52-week high at 25.35 USD - Investing.com
Centessa Pharmaceuticals (CNTA) – Research Analysts’ Weekly Ratings Changes - Defense World
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025 - GlobeNewswire Inc.
Mario Alberto Accardi Sells 8,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Centessa Pharma (CNTA) president sells $200k in shares - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at $24.65 - Investing.com India
Centessa Pharmaceuticals stock hits 52-week high at $24.65 By Investing.com - Investing.com Philippines
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Windmill Hill Asset Management Ltd - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Reduced by GAMMA Investing LLC - Defense World
Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler - The Globe and Mail
Tanager Wealth Management LLP Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Platinum Investment Management Ltd. Has $3.82 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Wells Fargo Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 12-Month HighWhat's Next? - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD By Investing.com - Investing.com Nigeria
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of “Buy” by Brokerages - Defense World
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD - Investing.com India
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year HighTime to Buy? - MarketBeat
Centessa Pharmaceuticals’ Bush sells $840,000 in shares - Investing.com India
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) CTO Sells $840,000.00 in Stock - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – Should You Buy? - Defense World
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 8,172 Shares of Stock - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD By Investing.com - Investing.com Australia
Centessa Pharmaceuticals (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD - Investing.com
Woodline Partners LP Lowers Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Ellsworth Advisors LLC Buys Shares of 48,872 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Fred Alger Management LLC Has $2.11 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharma general counsel sells $131k in shares By Investing.com - Investing.com South Africa
Centessa Pharma general counsel sells $131k in shares - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year HighShould You Buy? - MarketBeat
Finanzdaten der Centessa Pharmaceuticals Plc Adr-Aktie (CNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):